Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

A diabetic coma is a severe complication from extreme blood sugar levels requiring prompt recognition and management to ...